NCT07312877

Brief Summary

This study aims to compare the effects of intraoperative intravenous lidocaine and intravenous remifentanil on postoperative pain management in patients undergoing laparoscopic cholecystectomy under general anesthesia. Although laparoscopic procedures are minimally invasive, patients frequently experience postoperative pain. Multimodal analgesia techniques are recommended to optimize pain control and recovery while minimizing opioid-related adverse effects. In this prospective observational study, adult patients (ASA I-II) aged over 18 years who provided written informed consent were included. Standard intraoperative monitoring was performed. Anesthesia induction consisted of fentanyl, lidocaine, propofol, and rocuronium, with maintenance using sevoflurane. Hemodynamic parameters were recorded throughout the procedure. For postoperative analgesia, intravenous paracetamol and tramadol were administered before the end of anesthesia. The primary objective is to evaluate whether intravenous lidocaine provides postoperative analgesic efficacy and recovery quality comparable to remifentanil, and to determine its potential role as an opioid-sparing alternative in laparoscopic cholecystectomy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
138

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2025

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 25, 2025

Completed
5 days until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2025

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

December 3, 2025

Completed
28 days until next milestone

First Posted

Study publicly available on registry

December 31, 2025

Completed
Last Updated

August 12, 2026

Status Verified

August 1, 2026

Enrollment Period

8 months

First QC Date

December 3, 2025

Last Update Submit

August 10, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Postoperative Pain Score (NRS)

    Postoperative pain intensity will be assessed using the Numeric Rating Scale (NRS; 0 = no pain, 10 = worst pain imaginable). Pain scores at rest will be assessed at 30 minutes and at 2, 6, 12, and 24 hours postoperatively. The comparison between the lidocaine and remifentanil groups will determine the effect of intraoperative intravenous lidocaine versus remifentanil on postoperative analgesia.

    Within 24 hours after surgery

Secondary Outcomes (7)

  • time to first rescue analgesia

    From the end of surgery until the first administration of rescue analgesia, up to 24 hours postoperatively.

  • Postoperative Analgesic Requirement

    First 24 hours postoperatively

  • Recovery Profile

    First 24 hours postoperatively

  • Postoperative nausea and vomiting

    First 24 hours postoperatively

  • Time to first mobilization

    From the end of surgery until first mobilization, up to 24 hours postoperatively.

  • +2 more secondary outcomes

Study Arms (2)

Lidocaine Group

Patients received IV lidocaine (1 mg/kg bolus + infusion) during laparoscopic cholecystectomy

Drug: Lidocaine

Remifentanil Group

Patients received IV remifentanil infusion during laparoscopic cholecystectomy

Drug: Remifentanil

Interventions

Patients received intravenous lidocaine 1 mg/kg bolus followed by continuous infusion during laparoscopic cholecystectomy.

Lidocaine Group

Patients received intravenous remifentanil infusion during laparoscopic cholecystectomy.

Remifentanil Group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult patients (ASA I-II) undergoing elective laparoscopic cholecystectomy under general anesthesia at Prof. Dr. Cemil Taşçıoğlu City Hospital.

You may qualify if:

  • Patients over 18 years of age
  • ASA physical status I-II
  • Scheduled for elective laparoscopic cholecystectomy under general anesthesia
  • Provided written and verbal informed consent

You may not qualify if:

  • Allergy or contraindication to lidocaine, remifentanil, or study drugs
  • Severe cardiovascular, hepatic, or renal disease
  • Pregnancy or lactation
  • Conversion from laparoscopic to open cholecystectomy
  • Refusal to participate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Prof. Dr. Cemil Tascıoğlu City Hospital

Istanbul, Istanbul, 34384, Turkey (Türkiye)

Location

MeSH Terms

Interventions

LidocaineRemifentanil

Intervention Hierarchy (Ancestors)

AcetanilidesAnilidesAmidesOrganic ChemicalsAniline CompoundsAminesPropionatesAcids, AcyclicCarboxylic AcidsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
resident doctor

Study Record Dates

First Submitted

December 3, 2025

First Posted

December 31, 2025

Study Start

April 1, 2025

Primary Completion

November 25, 2025

Study Completion

November 30, 2025

Last Updated

August 12, 2026

Record last verified: 2026-08

Data Sharing

IPD Sharing
Will not share

Locations